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Abstract
Background: Estrogen is an established endometrial carcinogen. One of the most important
mediators of estrogenic action is the estrogen receptor alpha. We have investigated whether
polymorphic variation in the estrogen receptor alpha gene (ESR1) is associated with endometrial
cancer risk.
Methods: In 702 cases with invasive endometrial cancer and 1563 controls, we genotyped five
markers in ESR1 and used logistic regression models to estimate odds ratios (OR) and 95 percent
confidence intervals (CI).
Results: We found an association between rs2234670, rs2234693, as well as rs9340799, markers
in strong linkage disequilibrium (LD), and endometrial cancer risk. The association with rs9340799
was the strongest, OR 0.75 (CI 0.60–0.93) for heterozygous and OR 0.53 (CI 0.37–0.77) for
homozygous rare compared to those homozygous for the most common allele. Haplotype models
did not fit better to the data than single marker models.
Conclusion: We found that intronic variation in ESR1 was associated with endometrial cancer
risk.
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Background
Estrogens, whether from endogenous or exogenous
sources, are potent mitogens in the endometrium and
thus constitute a major carcinogen in this tissue [1].
Endometrial cancer is therefore a good model for investi-
gating clinical effects of estrogen signaling. Estrogen
receptor alpha is the principal estrogen receptor expressed
in the endometrium [2,3] and it is considered to be crucial
in the development of endometroid endometrial carci-
noma, the most common histological subtype among
endometrial neoplasms [1]. Since altered ER function
could have impact on the risk of endometrial cancer, the
estrogen receptor alpha gene (ESR1) is a plausible
endometrial cancer candidate gene which has been inves-
tigated in a few studies [4-6]. We have investigated
whether polymorphic variation in the ESR1 is associated
with invasive endometrial cancer risk, overall and in sub-
groups defined by other hormonally related factors.
Methods
Parent study
This nation-wide population-based case-control study
encompassed all cases of incident, primary histopathologi-
cally confirmed invasive endometrial cancer among women
50 to 74 years of age resident in Sweden between January 1,
1994 and December 31, 1995 as previously described in
detail [7]. Endometrial cancer patients were identified at
diagnosis through a notification system organized within the
six Swedish regional cancer registries, to which reporting of
all malignant tumors is mandatory. Controls were women
randomly selected in 5-year age strata (to match the expected
age frequency distribution among the cases) from the Swed-
ish Total Population Register. Only women with an intact
uterus and no previous history of endometrial cancer were
eligible for this study.
Endometrial cancer patients were asked to participate by
their respective physicians. After their informed consent,
we mailed self-administered questionnaires asking for
detailed information about use of menopausal hormones
and oral contraceptives, weight, height, reproductive his-
tory, medical history, and other lifestyle factors. Controls
were contacted directly with the questionnaire. Seventy-
six percent of eligible cases (n = 802) and 84 percent of the
controls (n = 3 550) ultimately participated in the parent
study by answering the questionnaire. Among these con-
trols, 491 who failed to return the mailed questionnaire
were interviewed by phone. Slides with tumor tissue were
collected from all cases and reviewed by one study pathol-
ogist to confirm the diagnosis, and to document tumor
grade and myometrial invasion. The specimens were
reclassified as: endometroid adenocarcinoma (n = 648),
seropapillary carcinoma (n = 36), clear cell carcinoma (n
= 10), adenoacanthoma (n = 3), adenosquamous carci-
noma (n = 12), endometrial atypical hyperplasia (n = 80)
(adenomatous hyperplasia with slight, moderate or
severely pronounced atypia), and anaplastic carcinoma (n
= 13). Results from the parent study have been published
[7-10].
Selection of present study population
In the analysis, we included all women with endometrial
cancer (n = 802) and 802 randomly selected controls (fre-
quency-matched by age) from the parent study. In order
to increase statistical power in subgroup analyses, we
additionally selected all remaining eligible controls who
had taken menopausal hormone treatment, either prepa-
rations containing medium potency estrogen only
(mainly estradiol or conjugated estrogens) or medium
potency estrogen in combination with progestin for at
least 2 years (277 controls) and all remaining control
women with self-reported diabetes mellitus (124 con-
trols). For a detailed description of the hormone treat-
ment variables, please see [8]. In total, 802 cases and 1
203 controls were selected. In addition, we included 871
controls from the parent study who had also participated
and been genotyped in a parallel breast cancer study, who
fulfilled the inclusion criteria (including having an intact
uterus). The Institutional Review Board at Karolinska
Institutet, Stockholm, Sweden and the six other Swedish
regional review boards approved this study.
Collection of biological material
All selected living women were contacted by mail and
those who gave informed consent received a blood sam-
pling kit by mail. Whole blood samples were drawn at a
primary health care facility close to the woman's home
and were sent to us by standard mail. A majority of the
samples arrived at Karolinska Institutet within 24 hours
after blood draw. All blood samples were immediately
stored at -20°C. Endometrial cancer cases who declined to
donate a blood sample were asked to permit to our use of
normal tissue from archived paraffin embedded tissue
taken at cancer surgery (consisting of, for example, cancer-
free lymph nodes, uterine tube or myometrium). We also
attempted to retrieve archived tissue samples from all
deceased endometrial cancer cases. Samples were coded
and transferred to the laboratories. Blood samples or
archived tissue samples were obtained for 603 and 104
endometrial cancer patients, respectively, and blood sam-
ples from in total 1 574 control women (922 selected for
this study + 652 genotyped in the breast cancer study),
yielding participation rates of 88 percent for cases (707 of
802 eligible) and 76 percent for controls (1 574 of 2 074
eligible). Considering also the participation rate in the
parent study, overall participation rates were 67 percent
and 64 percent among cases and controls, respectively.
Selection of SNPs and microsatellite markers
We selected ESR1 polymorphisms to be analyzed from the
literature [11-14]. The polymorphisms were not intended
to capture variation across the entire gene. The 5' pro-BMC Cancer 2008, 8:322 http://www.biomedcentral.com/1471-2407/8/322
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moter microsatellite (TAn) rs2234670 is located -1174-
base pairs upstream of exon 1, while the SNPs rs2234693
(also known as PvuII) and rs9340799 (also known as
XbaI) are found in intron 1, and the synonymous coding
rs4986934 (codon 243 CGC>CGT) and rs1801132 SNPs
(codon 325 CCC>CCG) are located in exon 3 and 4,
respectively.
DNA extraction
DNA was isolated from 3 ml whole blood using the Wiz-
ard Genomic DNA Purification Kit (Promega, Madison,
WI, USA) according to the manufacturer's instructions.
From non-malignant cells in paraffin embedded tissue,
we extracted DNA using a standard phenol/chloroform/
isoamylalcohol protocol [15].
Genotyping methods
SNPs and microsatellite markers
All primers and probes for the 5' promoter microsatellite
rs2234670, the intron 1 SNPs rs2234693 and rs9340799,
and the synonymous exonic rs4986934 and rs1801132
SNPs, were designed based on the reference sequences
AF082876, AF326912 and NM_000125, respectively. For
the fluorescence polarization and the minisequencing
assays [16], we designed minisequencing primers comple-
mentary to the sequence immediately adjacent to the
SNPs. For the Molecular Beacon assay [17], we designed
two fluorescently labeled allele specific probes for each
SNP, carrying the variable position in the middle of the
loop region [18]. We used a web-based DNA folding pro-
gram (mfold) [19] to estimate the stability of the stem and
loop structure of the MB probes. Supplementary tables 1
and 2 (Additional file 1) give the primer and probe
sequences and their modifications.
Minisequencing assay using fluorescence polarization detection
The region containing the intron 1 SNPs, rs2234693 and
rs9340799, was amplified in one PCR fragment. PCR was
performed using 20 ng of genomic DNA, 0.02 U/μl Taq
Gold DNA polymerase (Applied Biosystems, Foster City,
CA, USA), 100 μM dNTPs (Amersham Pharmacia Biotech,
Uppsala, Sweden) and 0.1 μM of both PCR primers in 30
μl of GeneAmp PCR buffer supplied with the enzyme at
95°C for 7 minutes, followed by 40 cycles at 92°C for 15
seconds, 56°C for 1 minute and 72°C for 45 seconds. Five
microliters of PCR product was aliquoted to 384-well
microtiter plates and 5 μl of a PCR cleanup mixture con-
taining 0.1 U/μl shrimp alkaline phosphatase (USB Cor-
poration, Cleveland, OH) and 0.1 U/μl Exonuclease I
(USB Corporation) in 20 mM Tris-HCl pH 8.0 and 10 mM
MgCl2 was added.
The plate was incubated at 37°C for 1 hour, followed by
15 minutes at 95°C to inactivate the enzymes. Five micro-
liters of extension mixture containing 5 μM extension
primers, and 0.08 U/μl Thermosequenase (Amersham
Pharmacia Biotech) in 50 mM Tris-HCl pH 9, 50 μM KCl,
5 mM NaCl, 5 mM MgCl2, 8% glycerol, and fluorescently
labeled and unlabeled ddNTPs was added to each reac-
tion. The two ddNTPs relevant for the particular SNP were
labeled and included at a 1:5 ratio relative to unlabeled
ddNTPs. The total concentration of ddNTP was 0.125 μM.
The fluorescent dye rhodamine 110 (R110) was used to
label ddGTP and ddCTP, and 6-carboxytetramethylrhod-
amine (TAMRA) were used to label ddATP and ddUTP
(PerkinElmer Life Sciences, Boston, MA, USA). The cyclic
extension reaction was performed at 92°C for 1 minute
followed by 40 cycles of 92°C for 10 seconds and 55° for
30 seconds. The fluorescence signals in the 384 well plates
were read on an Analyst AD™ (Molecular Devices Corpo-
ration, Sunnyvale, CA, USA). Genotypes were assigned
using the software AlleleCaller ™ supplied with the instru-
ment, and a custom-made Excel macro. In each run, posi-
tive controls for the three genotypes and negative controls
were included. Both DNA polarities were analyzed and
the results were concordant in all samples. Approximately
30 percent of the assays were repeated and the results were
identical. In addition, 3% of the genotypes were validated
by solid-phase minisequencing.
Molecular Beacon assay
To analyze the exonic SNPs rs4986934 and rs1801132, 10
ng of genomic DNA was amplified in a 25 μl reaction con-
taining 0.02 U/μl of AmpliTaq Gold DNA polymerase
(Applied Biosystems), 3.5 mM MgCl2, 250 μM of dNTPs
(Amersham Pharmacia Biotech) and 1 μM of PCR primers
in TaqMan Buffer A containing the ROX dye (Applied Bio-
systems). The two MB probes were included at 0.34 μM
concentration. The cycling conditions were 95°C for 10
minutes, followed by 40 cycles at 95°C for 30 seconds,
55°C (rs1801132) or 57°C (rs4986934) for 1 minute and
72°C for 45 seconds and was performed using an ABI
Prism 7700 Sequence Detection System (Applied Biosys-
tems). The increase in fluorescent signal was registered
during the annealing step of the reaction and the end-
point signals were used to assign the genotypes as previ-
ously described [18]. In each run, positive controls for the
three genotypes and negative controls were included.
Both possible nucleotides of the SNP were interrogated in
the same reaction. Approximately 3% of the assays were
repeated and the results were identical. Two percent of the
assays were validated by solid-phase minisequencing. The
Molecular Beacon assay has previously been quantita-
tively validated in our laboratory [18].
Solid-phase minisequencing assay
Solid-phase minisequencing in microtiter plates [20] was
used in part to genotype rs4986934. The assay also served
as a reference method for the other SNP assays.BMC Cancer 2008, 8:322 http://www.biomedcentral.com/1471-2407/8/322
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Microsatellite assay
The dinucleotide repeat rs2234670 region was amplified
using an ABI-877 Integrated Thermal cycler PCR robot
with standard reagents (Applied Biosystems) [21]. The
cycling conditions were 96°C for 10 minutes followed by
36 cycles of 30 seconds at 96°C, 30 seconds at 57°C, and
1 minute at 72°C with a final extension step for 7 min-
utes. The HEX-labeled fluorescent PCR products were
mixed with an internal-lane standard (GS-500 TAMRA)
and separated on a 6% polyacrylamide gel using a 96-well
ABI 377 automatic sequenator. Gel data were analyzed
using Genescan Analysis 3.1 and allele sizes were deter-
mined using Genotyper 2.0 (all Applied Biosystems). In
each run, 2–3 negative controls were included. Approxi-
mately 1% of the assays were repeated and gave concord-
ant results. After calculation of actual number of TA
repeats there was no difference between repeated runs of
the same sample. The assay was validated by control
sequencing of three different repeat lengths.
Statistical Methods
We verified that genotype frequencies among controls
were in accordance with expectations under Hardy-Wein-
berg equilibrium (HWE) using χ2 statistics. We considered
the rs2234670 in its original form, as 8 categories, or
dichotomized, into long and short (≤ 14 or > 14 repeats),
as the TAn lengths were bimodally distributed with peaks
at 11 and 18 repeats, with a dip at 14 repeats. In addition,
we estimated pairwise linkage disequilibrium values |D'|
and r2 [22,23].
We used conditional logistic regression to calculate odds
ratios (OR) and 95 percent confidence intervals (CI) for
association between single loci genotypes and endome-
trial cancer risk. We conditioned on the variables used for
selection, i.e. age in 5-year categories, use of menopausal
hormones for two years or more, and self-reported diabe-
tes mellitus.
We tested for associations between ESR1 polymorphisms
and other covariates by scrutinizing 3 × k tables and calcu-
lating  χ2 statistics. Covariates that were approximately
normally distributed (body mass index (BMI, weight in
kg/height in m2) and age at menopause) were tested by
means of two-sample t test over genotype categories. The
following covariates were considered: age (in 5-year age
groups), use of any preparation containing medium
potency estrogen with or without added progestin (never,
< 2 years, ≥ 2 years), use of preparation containing only
medium potency estrogen without progestin (never, < 2
years, ≥ 2 years), BMI (< 25, 25–27.99, ≥ 28 or as a contin-
uous variable), age at menopause (in tertiles among con-
trols or as continuous variable), parity (nulliparous, 1
childbirth, ≥ 2 childbirths), smoking at least 100 cigarettes
in their lifetime or regularly for at least 1 year (ever,
never), use of combined oral contraceptives (ever, never),
age at last birth (tertiles or as a continuous variable, only
including women who ever had given birth), and age at
menarche (tertiles or as a continuous variable). For
detailed descriptions of how the above variables were
defined, please see [8]. All covariates were introduced into
the logistic regression model to detect any indications of
confounding or other associations potentially affecting
the primary association between genotypes and endome-
trial cancer. We used likelihood ratio (LR) tests test to
compare successive models, all of which included the
same set of endometrial cancer cases and controls. We per-
formed these analyses using the SAS system (Release 8.02,
SAS Institute Inc. Cary, NC, USA).
We tested for disease-haplotype association using likeli-
hood-based approaches contained in the software EH
plus [24] as well as in routines written in the S-PLUS
(Insightful) programming language. Most available soft-
ware (including EH plus) for testing association between
haplotypes and case/control status assume multiplicative
penetrance, that is, the OR comparing two haplotype cop-
ies against none is assumed to be the square of the OR
comparing one against none.
Results
We successfully genotyped 695 cases and 1564 controls
for the rs2234670, 698 cases and 1561 controls for the
rs2234693, 698 cases and 1562 controls for the
rs9340799, 701 cases and 1563 controls for the
rs4986934, and 702 cases and 1563 controls for the
rs1801132 marker. In controls, SNP genotype frequencies
were in HWE but the rs2234670 genotype frequencies
were not, whether in dichotomised form (p = 0.003) or
when all alleles were considered (p < 0.0001).
The two intron 1 markers were in strong LD while there
was weaker pairwise LD between the remaining markers
(Table 1).
Risk factor exposure differences between cases and con-
trols reflected established associations (Table 2). Ninety-
three percent of the tumours in the following analyses
were of endometroid histological type. Myometrial inva-
sion was available for 79 percent of the cases, out of which
31 percent had invasion through more than half of the
myometrial thickness. Thirty-eight, 45 and 17 percent
were of histopathological grade 1, grade 2, and grade 3,
respectively. We found no convincing associations
between genotypes and any of the covariates (data not
shown). There was no difference in genotype frequencies
between cases who donated blood samples and those
who participated via tissue samples (P = 0.96, 0.66, 0.48,
0.56, and 0.51 for rs2234670, rs2234693, rs9340799,
rs4986934, and rs1801132, respectively) or between pri-BMC Cancer 2008, 8:322 http://www.biomedcentral.com/1471-2407/8/322
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mary selected controls and controls included after they
had been genotyped for the parallel breast cancer study (P
= 0.52, 0.98, 0.77, 0.31, 0.29 for rs2234670, rs2234693,
rs9340799, rs4986934, and rs1801132, respectively). Fur-
ther, genotype frequencies did not differ between those
included in multivariate models and those excluded due
to missing information about one or more of the included
covariates (data not shown). Cancers in women partici-
pating via tissue samples were more often of more
advanced stage as measured by degree of myometrial
invasion (no invasion 2.8 vs 10.5 percent, less than half of
the myometrial thickness 65.3 vs 61.7 percent, more than
half of the myometrial thickness 26.4 vs 25.9 percent,
through the serosa 5.6 vs 1.9 percent, p = 0.05).
Non-participants, i.e. those that were eligible for this
study but that either were not selected or did not consent
to participate, were on average older than participants.
Non-participating cases more often had cancer with more
advanced myometrial invasion; 50 percent had cancer
invasion to more than half of the myometrial thickness as
compared to 31 percent among participants (p < 0.0001).
Participants were also more likely to have been oral con-
traceptives users. Due to the over-sampling scheme, par-
ticipants were also more likely to have used menopausal
hormones. Despite our over-sampling of women with
diabetes mellitus, participants were less likely to have this
disease than non-participants. Participants and non-par-
ticipants were similar with regard to smoking habits, fam-
ily history of endometrial cancer, BMI, age at last birth
and age at menopause (data not shown).
Association with endometrial cancer
In univariate analyses conditioned on the selection varia-
bles the rs2234670, the rs2234693 and the rs9340799
were associated with endometrial cancer risk so that sub-
jects homozygous for the rarer alleles (denoted 11 in
Table 3) were at decreased risk as compared to homozy-
Table 1: Pairwise linkage disequilibrium between polymorphisms in the estrogen receptor alpha gene
rs2234670a rs2234693 rs9340799 rs4986934 rs1801132
|D'|
rs2234670a - 0.790 0.734 0.046 0.188
rs2234693 0.571 - 0.998 0.825 0.338
rs9340799 r2 0.349 0.590 - 0.742 0.245
rs4986934 0.001 0.023 0.011 - 0.822
rs1801132 0.008 0.029 0.009 0.090 -
|D'|-values above diagonal and r2-values below.
a For |D'| rs2234670 Tan repeat lengths were divided into eight categories, <10, 11, 12–13, 14–16, 17, 18, 19 or > 20. This ensured that there were 
few cells that contained less than five observations. For r2 the Tan repeat is dichotomized.
Table 2: Distribution of endometrial cancer risk factors among participating endometrial cancer cases and population controls
Co-variate Cases/controls Cases Controls
N Mean (SD) P value
Age 702/1563 64.1 (6.80) 63.4 (7.03) 0.0001
Age at menarche 653/1427 13.5 (1.37) 13.5 (1.42) 0.14
Age at last birth 604/1405 29.4 (5.08) 30.4 (5.34) 0.0002
Age at menopause 614/1503 51.0 (4.06) 50.1 (3.91) <0.0001
Recent BMI 701/1546 27.4 (5.31) 25.5 (4.27) <0.0001
Percent
Nulliparous 158/97 14 10
1 childbirth 289/146 21 18 0.008
2+ childbirths 1116/459 65 71
Family historya 667/1397 10 5 <0.0001
Diabetes Mellitus, self-reportedb 702/1441 10 8 0.17
Ever use of oral contraceptives 699/1550 24 36 <0.0001
Ever use of menopausal hormonesb 690/1541 28 28 0.97
Smokingc 702/1563 35 43 0.0004
a Family history is defined as having a mother or a sister with endometrial cancer.  bWomen with self-reported diabetes mellitus and those who had 
used menopausal hormones containing medium potency estrogens were over-sampled into the study and thus the proportions do not reflect 
known case-control differences c Smoking is defined as a participant having smoked at least 100 cigarettes during her lifetime or having smoked 
regularly for at least one yearBMC Cancer 2008, 8:322 http://www.biomedcentral.com/1471-2407/8/322
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gotes for the most common allele (denoted 00). None of
the covariates appeared to be confounders. However,
including information about parity, BMI, smoking status
and use of oral contraceptives significantly improved the
model fit. Age at last birth and age at menopause further
bettered model fit but since adjustment left point esti-
mates unchanged these variables were excluded due to
missing information in many individuals. Multivariate
analyses yielded slightly stronger results compared to
those from univariate analyses (Table 3). The difference
could not be attributed to any one variable. Heterozygotes
were at intermediate risk. Excluding cases with DNA
derived from tissue left estimates largely unaltered and
associations using cases with tissue derived DNA did not
speak against pooling all successfully genotyped cases in
the further analysis (Additional file 1, Supplementary
table 3).
We examined whether including more than one marker
would improve model fit, indicating influence on risk by
combinations of alleles at different loci (i.e. haplotype
effects). The association with rs9340799 was the strong-
est. The addition of either rs2234670 or rs2234693 to a
model with rs9340799 did not significantly improve
explanation of disease status (LR test p = 0.70 and p =
0.50, respectively). Conversely, starting with rs2234670
or rs2234693 and adding rs9340799 significantly
improved model fit (LR test p = 0.02 and p = 0.03, respec-
tively). Adding any of the last two markers, rs4986934 or
rs1801132, neither improved fit nor changed estimates
nor confidence intervals for the first three markers consid-
ered one at the time. When adding to the model with
rs9340799 also rs2234693 and the interactions between
these loci, the fit was not improved (LR test, p = 0.48).
Neither did adding the rs1801132 (LR test p = 0.31) or the
rs2234670 (LR test p = 0.83) and the respective interac-
tions improve fit. Only three out of the four possible hap-
lotypes of rs9340799 and rs2234693 existed in our study
population (Table 4), so that we were unable to compare
the model containing rs9340799 and rs2234693 main
effects and interactions with the haplotype model. Other
haplotype models (under the assumption of multiplica-
tive penetrance), using rs9340799 and one of rs2234670
or rs1801132, did not provide a significant improvement
in fit over the single locus (rs9340799) model.
We investigated the association between rs9340799 and
endometrial cancer stratified by the covariates (Table 5).
We were primarily interested in potential interactions
between the marker and use of menopausal hormones
and BMI, since these factors are the most important deter-
minants of serum estrogen levels in postmenopausal
women, though we also examined other hormonally
related variables. We could not estimate main effects of
variables that we used in our sampling scheme (see Meth-
ods section) and thus the results presented (first in Table
5) from the analyses stratified by these factors convey only
genetic effects. In subdividing the cases and controls by
use of menopausal hormones, the protective effect of
rs9340799 emerged among never users while the pattern
was unclear among users, possibly due too small numbers
of observations (Table 5). P-values for interaction were
0.007, 0.35, and 0.08 for compounds containing estrogen
only, estrogen plus progestins cyclically and estrogen plus
progestins continuously, respectively. Despite the small p-
values, there were no allele-dose response relations. Asso-
ciation analyses stratified by various other risk factors for
endometrial cancer are given in Table 6. BMI did modify
the association between rs9340799 and endometrial can-
cer (p = 0.91). This result was not sensitive to BMI cate-
gory cutpoints (p = 0.75 and p = 0.45 using BMI>30 or
BMI>31 as the highest category, respectively). The protec-
Table 3: Odds ratios (OR) for endometrial cancer and 95% confidence intervals (CI)
Marker rs2234670 rs2234693 rs9340799 rs4986934 rs1801132
Genotype 00a Case/controls 232/441 211/382 324/573 617/1276 406/834
OR (CI) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
01a Case/controls 307/618 336/670 280/632 44/89 226/468
OR (CI) Univariateb 0.95 (0.75–1.19) 0.88 (0.70–1.11) 0.79 (0.64–0.98) 1.02 (0.68–1.54) 1.02 (0.82–1.26)
Multivariatec 0.92 (0.72–1.16) 0.86 (0.68–1.10) 0.75 (0.60–0.93) 1.03 (0.67–1.58) 1.00 (0.80–1.26)
11a Case/controls 123/309 115/316 58/163 1/3 30/66
OR (CI) Univariateb 0.72 (0.54–0.97) 0.65 (0.48–0.87) 0.59 (0.41–0.85) 0.94 (0.09–9.40) 0.94 (0.58–1.51)
Multivariatec 0.73 (0.54–0.99) 0.65 (0.48–0.89) 0.53 (0.37–0.77) 1.02 (0.09–11.61) 0.95 (0.58–1.57)
Univariate results include individuals with complete information about the covariates used in the multivariate analysis.
a The genotypes are rs2234670: 00 = ≤ 14/≤ 14, 01 = ≤ 14/> 14, 11 => 14/> 14; rs2234693: 00 = T/T, 01 = T/C, 11 = C/C; rs9340799: 00 = A/A, 01 
= A/G, 11 = G/G; rs4986934: 00 = C/C, 01 = C/T, 11 = T/T; rs1801132: 00 = C/C, 01 = C/G, 11 = G/G. b Long-term users of menopausal 
hormones and diabetics were over-sampled, thus logistic regression models are conditioned for age- and sampling category, which means that only 
those with complete information about hormone use and diabetes mellitus were included. c Multivariate models are adjusted for parity 
(continuous), BMI (continuous), smoking (ever, never) and use of oral contraceptives (ever, never)BMC Cancer 2008, 8:322 http://www.biomedcentral.com/1471-2407/8/322
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tive effect of rs9340799 was clearer among non-smokers
and among non-users of combined oral contraceptives
although tests for interaction were non-significant (p =
0.17 and p = 0.19, respectively). There appeared to be no
modification of the association between rs9340799 and
endometrial cancer risk by use of oral low potency estro-
gen (p = 0.50), diabetes mellitus (p = 0.91), parity (p =
0.88), age at menopause (in tertiles, p = 0.72), age at last
birth (in tertiles, p = 0.46), or family history of endome-
trial cancer (p = 0.51).
Only 45 cases were of non-endometroid histotype.
Excluding these from the analyses did not change the
results of any of the above analyses (data not shown).
Analyses where cases were stratified by degree of myome-
trial invasion (Additional file 1, Supplementary table 3)
indicated a more pronounced protective effect of the
rs9340799 variant allele among those with invasion
through more than 50 percent of the myometrium
(adjusted OR 0.67 CI 0.45–0.98 for heterozygotes and OR
0.35 CI 0.16–0.75 for variant allele homozygotes). This
latter analysis was based on only 139 cases. Stratifying on
histopathological grade did not reveal any clear pattern to
indicate a differential effect of genotype on risk for
endometrial cancers of various degree of differentiation
(Additional file 1, Supplementary table 4).
Discussion
We show that non-coding variation in ESR1 is associated
with endometrial cancer risk. With regard to the
rs9340799 locus, homozygotes for the rare G allele had an
almost halved risk for endometrial cancer compared to
common allele homozygotes. This protection seemed
more pronounced when only cases with invasion through
more than 50 percent of the myometrium were consid-
ered. The latter analysis was based on few cases and needs
further confirmation. We found no convincing modifica-
Table 4: Distribution of ESR1 four-locus haplotype frequencies as estimated through EM algorithms among endometrial cancer cases 
and population controls
Locus Proportion estimated to carry haplotype
rs2234693 rs9340799 rs4986934 rs1801132 Controls (n = 1560) All cases
(n = 694)
Endometroid cases
(n = 647)
T A C C 0.371 0.404 0.406
C G C C 0.288 0.255 0.252
C A C C 0.114 0.118 0.118
T A C G 0.123 0.137 0.135
C G C G 0.055 0.045 0.046
T A T G 0.028 0.025 0.027
Proportion accounted for by the most common haplotypes: 0.979 0.984 0.984
Table 5: Odds ratios (OR) and 95% confidence intervals (CI) estimating the association between ESR1 rs9340799 and endometrial 
cancer by subgroups of hormone use and self-reported diabetes mellitus
ORs and CIs for rs9340799 genotypesa
Covariate Cases/controls A/A A/G GG
Use of menopausal hormones with medium potency estrogens
Never users 485/1006 1 (ref) 0.78 (0.62–0.97) 0.51 (0.34–0.77)
Ever use of estrogen only 85/104 1 (ref) 0.47 (0.23–0.97) 1.96 (1.62–6.14)
Ever use of estrogen plus progestins cyclically 100/196 1 (ref) 0.85 (0.49–1.49) 0.78 (0.33–1.84)
Ever use of estrogen plus progestins continuously 38/145 1 (ref) 0.57 (0.24–1.35)
p = 0.08b
0.94 (0.29–3.08)
Diabetes Mellitus 598/1258 1 (ref) 0.76 0.56
No (0.61–0.94) (0.39–0.81)
Yes 64/110 1 (ref) 0.52 (0.25–1.09)
p = 0.91b
0.57 (0.15–2.15)
a Analyses were conditioned on age, hormone use for more than two years, and diabetes mellitus b Test for interactions with variables used for 
selection were designed to test if the terms for the two (two level covariate) or four (three level covariate) extra combined categories were 
different from zero in a model containing the main effect of genotype and covariate. For medium potency estrogen variables the test was carried 
out comparing ever use with never use of any medium potency estrogens.BMC Cancer 2008, 8:322 http://www.biomedcentral.com/1471-2407/8/322
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tion of this association by other endometrial cancer risk
factors or histopathological grade.
We found no evidence of additional effects of other mark-
ers than rs9340799. However, we cannot determine
whether this SNP is functional or in LD with some other
functional locus. Furthermore, we cannot be completely
certain that rs9340799 is more influential than rs2234693
because of the strong LD between these markers, sepa-
rated by only 46 bp.
The association between rs9340799 and endometrial can-
cer was not convincingly modified by exposures that alter
the availability of estradiol or estrone such as use of men-
opausal hormone preparations or high BMI. In our paral-
lel breast cancer study [25] the ESR1-disease risk
association was stronger in women with high BMI but this
appeared not to be the case in endometrial cancer. The
effect of rs9340799 was largely the same in any stratum
with sufficient sample size.
Our study is population-based and the largest investigat-
ing the relation between ESR1 and endometrial cancer to
date. Furthermore, the study population is genetically
homogenous, which limits concern about population
stratification and which also preserves power as no addi-
tional stratifications based on ethnicity need to be made.
The vast majority of cases in this study were of the strongly
estrogen related endometroid type, and thus constitute a
Table 6: Odds ratios (OR) and 95% confidence intervals (CI) estimating the association between ESR1 rs9340799 and endometrial 
cancer by subgroups of other endometrial cancer risk factors
ORs and CIs for rs9340799 genotypea
Covariate Case/contl A/A A/G GG P for interaction
Use of oral low potency estrogen (estriol)
Never 533/1213 1 (ref) 0.79 (0.64–0.99) 0.55 (0.37–0.81)
Ever 127/153 1.77 (1.20–2.61) 1.28 (0.86–1.92) 1.52 (0.74–3.15) 0.50
BMI (kg/m2)
< 25 265/698 1 (ref) 0.83 (0.61–1.13) 0.62 (0.37–1.03)
25–28 136/387 1.01 (0.71–1.45) 0.70 (0.48–1.02) 0.59 (0.27–1.27)
> 28 261/283 2.90 (2.05–4.11) 2.05 (1.46–2.87) 1.39 (0.80–2.43) p = 0.93
Smokingb
Never 434/783 1 (ref) 0.84 (0.05–1.08) 0.51 (0.33–0.80)
Ever 228/585 0.75 (0.56–1.00) 0.50 (0.37–0.68) 0.59 (0.35–0.98) p = 0.17
Use of combined oral contraceptives
Never 500/863 1 (ref) 0.86 (0.68–1.09) 0.58 (0.38–0.87)
Ever 162/505 0.63 (0.46–0.87) 0.38 (0.27–0.54) 0.43 (0.24–0.78) p = 0.19
Parity
0 childbirths 94/137 1 (ref) 0.78 (0.44–1.38) 0.44 (0.16–1.24)
1 childbirth 135/251 0.69 (0.41–1.18) 0.62 (0.37–1.04) 0.51 (0.23–1.11)
≥ 2 childbirths 433/980 0.62 (0.39–0.96) 0.45 (0.29–0.70) 0.37 (0.21–0.65) p = 0.88
At at menopause (years)
< 50 157/447 1 (ref) 0.81 (0.53–1.20) 0.51 (0.25–1.05)
50–51.5 125/393 0.98 (0.64–1.48) 0.68 (0.45–1.04) 0.79 (0.40–1.55)
> 51.5 294/470 1.75 (1.23–2.51) 1.48 (1.03–2.12) 0.95 (0.54–1.66) p = 0.72
Age at last birth (years, among parous only)
≤ 27 209/364 1 (ref) 0.66 (0.46–0.97) 0.75 (0.40–1.41)
27.5–32.5 194/452 0.75 (0.52–1.09) 0.53 (0.36–0.79) 0.33 (0.17–0.64)
≥ 33 165/415 0.55 (0.37–0.81) 0.52 (0.35–0.77) 0.39 (0.20–0.75) p = 0.46
Family history of endometrial cancerc
No 564/1262 1 (ref) 0.78 (0.63–0.97) 0.63 (0.44–0.90)
Yes 65/67 2.56 (1.47–4.46) 1.28 (0.76–2.18) 1.48 (0.39–5.66) p = 0.51
a Analyses were conditioned on age, hormone use for more than two years, and diabetes mellitus b Smoking is defined as having smoked at least 100 
cigarettes or having smoked regularly for at least one year c Family history is defined as having a mother or a sister with endometrial cancer.BMC Cancer 2008, 8:322 http://www.biomedcentral.com/1471-2407/8/322
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sample in which functional ESR1 alterations are expected
to become evident.
The markers that we have studied here were selected
because they were known to be polymorphic according to
the literature available when the study was planned
(around 1996). They were not selected, as is usually the
case with current studies, in an attempt to represent the
entire gene. This is a weakness but it should not discredit
the reported association.
It appears as if the ESR1 gene is composed of three differ-
ent LD blocks [26]. All markers that are typed in the
present study are located within the first region, towards
the 5' end of the gene. We did not find evidence of any
interactions between markers, which would have indi-
cated that functional combinations of alleles exist in the
gene. We initially intended to investigate if we could
establish whether any SNP was functional or instead in
LD with a functional locus, by comparing a model with
genotype main effects and interactions, to a haplotype
model, using SNPs rs9340799 and rs2234693. If the hap-
lotype model had exhibited a significantly better fit then
there would have been indication that other, linked, un-
typed, SNPs were responsible for the association [27].
However, only three out of the four possible haplotypes of
rs9340799 and rs2234693 exist in our data, so that we
could not make this comparison. In contrast to our find-
ings in the parallel breast cancer study [25], a haplotype
model with rs9340799 and rs1801132 did not provide
any additional explanatory information.
Our main results replicate our own findings in a separate
but equivalent Swedish study population where we
observed associations of similar strength and magnitude
[6]. They also corroborate results of a small Japanese study
where rs9340799 GG and rs2234693 CC genotypes were
associated to a lower risk for endometrial cancer com-
pared to those homozygous for the common allele [4];
OR 0.26 (CI 0.09–0.79) and OR 0.23 (CI 0.07–0.82),
respectively. Another Japanese study found no such asso-
ciation [5] but a decreased risk with allele-dose effect with
the rare allele of a ESR1 codon 10 SNP.
Weel and colleagues found the rs2234693 CC genotype to
be associated with an earlier onset of natural menopause
[28], which would entail a lower risk of endometrial can-
cer, but we did not find any similar association, nor any
interaction between ESR1  genotype and age at meno-
pause.
There is no evidence in the literature that rs9340799
affects the amount or function of the estrogen receptor
protein. Herrington and colleagues found that the adja-
cent rs2234693 C allele produced an additional binding
site for the myb family of transcription factors [29]. Bind-
ing of B-myb to this site appeared to have the capability of
enhancing  ESR1  transcription. Since B-myb is in itself
estrogen responsive there is a possibility of a positive feed-
back loop that could amplify estrogenic response. It is
possible that in fact rs2234693 is the functional variant
and that our finding was due to the strong LD between the
markers in addition to random variation in the data.
Ongoing studies that include dense mapping of ESR1 var-
iants will give guidance as to what variants need to be fur-
ther functionally validated.
Although our results, which are in line with a priori theo-
ries, might indicate a true influence of ESR1 variation on
estrogen dependent phenotypes they could conceivably
be due to selection bias, a potential problem in case-con-
trol studies. Our participation rates, 88 and 76 percent
among cases and controls, respectively (67 and 64 percent
using those eligible for the parent study in the denomina-
tor) could lead to bias if participation were related to gen-
otype. Non-participating cases had a more advanced
disease as measured by myometrial invasion. If, for exam-
ple, a genetic variant is associated to severe cancer but not
to less severe cancer and the more severe cases are less
likely to participate because they have died, any associa-
tion with cancer overall would be biased towards the null.
Furthermore, genotype frequencies were not different
between participants who donated blood and those who
took part via a tissue sample, the latter of which were
more often deceased. Our results cannot be generalized to
include all endometrial cancer because there is data that
indicates differing etiologies between endometroid and
non-endometroid endometrial cancer [1].
Another possible mechanism for selection bias is if an
ESR1  variant influences a phenotype that differentially
affects ascertainment or recruitment probability among
cases and controls. In this case one would expect to find
case-control associations with multiple otherwise unre-
lated phenotypes. ESR1 variation has indeed been associ-
ated with a host of other outcomes such as coronary heart
disease [30], height [31], bone mineral density [32,33],
multiple sclerosis [34], cognitive impairment [35], and
age at menarche [36]. However, despite the diversity
among these outcomes there is reasonable evidence of eti-
ological roles for estrogen. Our comparisons of character-
istics among participants and non-participants do not
point to any plausible mechanism for selection bias as an
explanation to the observed association.
Conclusion
In conclusion, we found an association between genetic
variation in ESR1  and endometrial cancer risk; the
rs9340799 GG genotype was associated to an almost 50
percent decreased risk for endometrial cancer comparedBMC Cancer 2008, 8:322 http://www.biomedcentral.com/1471-2407/8/322
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to the AA genotype. Our results strengthen belief in this a
priori strong candidate gene but we cannot, based on our
data, establish the importance of any single genetic locus
within the gene.
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